Mazzuca Marc Q, Mata Karina M, Li Wei, Rangan Sridhar S, Khalil Raouf A
Vascular Surgery Research Laboratory, Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Vascular Surgery Research Laboratory, Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
J Pharmacol Exp Ther. 2015 Feb;352(2):291-304. doi: 10.1124/jpet.114.219865. Epub 2014 Dec 3.
Estrogen interacts with estrogen receptors (ERs) to induce vasodilation, but the ER subtype and post-ER relaxation pathways are unclear. We tested if ER subtypes mediate distinct vasodilator and intracellular free Ca(2+) concentration ([Ca(2+)]i) responses via specific relaxation pathways in the endothelium and vascular smooth muscle (VSM). Pressurized mesenteric microvessels from female Sprague-Dawley rats were loaded with fura-2, and the changes in diameter and [Ca(2+)]i in response to 17β-estradiol (E2) (all ERs), PPT (4,4',4''-[4-propyl-(1H)-pyrazole-1,3,5-triyl]-tris-phenol) (ERα), diarylpropionitrile (DPN) (ERβ), and G1 [(±)-1-[(3aR*,4S*,9bS*)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro:3H-cyclopenta(c)quinolin-8-yl]-ethanon] (GPR30) were measured. In microvessels preconstricted with phenylephrine, ER agonists caused relaxation and decrease in [Ca(2+)]i that were with E2 = PPT > DPN > G1, suggesting that E2-induced vasodilation involves ERα > ERβ > GPR30. Acetylcholine caused vasodilation and decreased [Ca(2+)]i, which were abolished by endothelium removal or treatment with the nitric oxide synthase blocker Nω-nitro-l-arginine methyl ester (L-NAME) and the K(+) channel blockers tetraethylammonium (nonspecific) or apamin (small conductance Ca(2+)-activated K(+) channel) plus TRAM-34 (1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole) (intermediate conductance Ca(2+)-activated K(+) channel), suggesting endothelium-derived hyperpolarizing factor-dependent activation of KCa channels. E2-, PPT-, DPN-, and G1-induced vasodilation and decreased [Ca(2+)]i were not blocked by L-NAME, TEA, apamin plus TRAM-34, iberiotoxin (large conductance Ca(2+)- and voltage-activated K(+) channel), 4-aminopyridine (voltage-dependent K(+) channel), glibenclamide (ATP-sensitive K(+) channel), or endothelium removal, suggesting an endothelium- and K(+) channel-independent mechanism. In endothelium-denuded vessels preconstricted with phenylephrine, high KCl, or the Ca(2+) channel activator Bay K 8644 (1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-3-pyridinecarboxylic acid methyl ester), ER agonist-induced relaxation and decreased [Ca(2+)]i were with E2 = PPT > DPN > G1 and not inhibited by the guanylate cyclase inhibitor ODQ [1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one], and showed a similar relationship between decreased [Ca(2+)]i and vasorelaxation, supporting direct effects on Ca(2+) entry in VSM. Immunohistochemistry revealed ERα, ERβ, and GPR30 mainly in the vessel media and VSM. Thus, in mesenteric microvessels, ER subtypes mediate distinct vasodilation and decreased [Ca(2+)]i (ERα > ERβ > GPR30) through endothelium- and K(+) channel-independent inhibition of Ca(2+) entry mechanisms of VSM contraction.
雌激素与雌激素受体(ERs)相互作用以诱导血管舒张,但其ER亚型和ER后舒张途径尚不清楚。我们测试了ER亚型是否通过内皮和血管平滑肌(VSM)中的特定舒张途径介导不同的血管舒张和细胞内游离Ca(2+)浓度([Ca(2+)]i)反应。将来自雌性Sprague-Dawley大鼠的加压肠系膜微血管用fura-2加载,并测量了对17β-雌二醇(E2)(所有ERs)、PPT(4,4',4''-[4-丙基-(1H)-吡唑-1,3,5-三基]-三苯酚)(ERα)、二芳基丙腈(DPN)(ERβ)和G1 [(±)-1-[(3aR*,4S*,9bS*)-4-(6-溴-1,3-苯并二氧杂环戊烯-5-基)-3a,4,5,9b-四氢:3H-环戊并(c)喹啉-8-基]-乙酮](GPR30)的直径和[Ca(2+)]i变化。在用去氧肾上腺素预收缩的微血管中,ER激动剂引起舒张并使[Ca(2+)]i降低,其顺序为E2 = PPT > DPN > G1,表明E2诱导的血管舒张涉及ERα > ERβ > GPR30。乙酰胆碱引起血管舒张并降低[Ca(2+)]i,去除内皮或用一氧化氮合酶阻滞剂Nω-硝基-L-精氨酸甲酯(L-NAME)以及K(+)通道阻滞剂四乙铵(非特异性)或蜂毒明肽(小电导Ca(2+)-激活的K(+)通道)加TRAM-34(1-[(2-氯苯基)二苯基甲基]-1H-吡唑)(中电导Ca(2+)-激活的K(+)通道)处理可消除这种作用,提示内皮衍生的超极化因子依赖性激活KCa通道。E2、PPT、DPN和G1诱导的血管舒张和[Ca(2+)]i降低不受L-NAME、TEA、蜂毒明肽加TRAM-34、iberiotoxin(大电导Ca(2+)-和电压激活的K(+)通道)、4-氨基吡啶(电压依赖性K(+)通道)、格列本脲(ATP敏感性K(+)通道)或去除内皮的影响,提示一种不依赖内皮和K(+)通道的机制。在用去氧肾上腺素、高KCl或Ca(2+)通道激活剂Bay K 8644(1,4-二氢-2,6-二甲基-5-硝基-4-[2-(三氟甲基)phenyl]-3-吡啶羧酸甲酯)预收缩的去内皮血管中,ER激动剂诱导的舒张和[Ca(2+)]i降低顺序为E2 = PPT > DPN > G1,且不受鸟苷酸环化酶抑制剂ODQ [1H-(1,2,4)恶二唑并(4,3-a)喹喔啉-1-酮]抑制,并显示出[Ca(2+)]i降低与血管舒张之间的相似关系,支持对VSM中Ca(2+)内流的直接作用。免疫组织化学显示ERα、ERβ和GPR30主要存在于血管中膜和VSM中。因此,在肠系膜微血管中,ER亚型通过不依赖内皮和K(+)通道的方式抑制VSM收缩的Ca(2+)内流机制,介导不同的血管舒张和[Ca(2+)]i降低(ERα > ERβ > GPR30)。